1. Induced Disease Models Products Anti-infection
  2. Genetically Engineered Disease Models Bacterial Antibiotic
  3. Tetracycline

Tetracycline  (Synonyms: MK-801 maleate)

Cat. No.: HY-A0107 Purity: ≥98.0%
SDS COA Handling Instructions

Tetracycline is a broad-spectrum antibiotic with oral activity. Tetracycline exhibits activity against a wide range of bacteria including gram-positive, gram-negative bacteria, chlamydiae, mycoplasmas and rickettsiae. Tetracycline can be used for the research of infections.

For research use only. We do not sell to patients.

Tetracycline Chemical Structure

Tetracycline Chemical Structure

CAS No. : 60-54-8

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
200 mg USD 60 In-stock
1 g USD 96 In-stock
5 g USD 190 In-stock
10 g USD 250 In-stock
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 33 publication(s) in Google Scholar

Other Forms of Tetracycline:

Top Publications Citing Use of Products

33 Publications Citing Use of MCE Tetracycline

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Tetracycline is a broad-spectrum antibiotic with oral activity. Tetracycline exhibits activity against a wide range of bacteria including gram-positive, gram-negative bacteria, chlamydiae, mycoplasmas and rickettsiae. Tetracycline can be used for the research of infections[1].

IC50 & Target

Tetracycline

 

Cellular Effect
Cell Line Type Value Description References
CCRF-CEM CC50
40.5 μM
Compound: tetracycline
Cytotoxicity against CEM cells after 5 days by MTT method
Cytotoxicity against CEM cells after 5 days by MTT method
[PMID: 17376679]
HaCaT IC50
8 μM
Compound: Tetracycline
Cytotoxicity against human HaCaT cells after 24 hrs by MTT assay
Cytotoxicity against human HaCaT cells after 24 hrs by MTT assay
[PMID: 34223166]
HeLa IC50
> 400 μg/mL
Compound: Tetracycline
Antiproliferative effect against HeLa cells after 48 hrs
Antiproliferative effect against HeLa cells after 48 hrs
[PMID: 17088489]
MCF7 IC50
41.6 μM
Compound: Tetracycline
Dark toxicity against human MCF7 cells assessed as decrease in cell viability by MTT assay
Dark toxicity against human MCF7 cells assessed as decrease in cell viability by MTT assay
[PMID: 29673980]
MG-63 IC50
180 μg/mL
Compound: Tetracycline
Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs
Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs
[PMID: 17088489]
Osteoblast IC50
180 μg/mL
Compound: Tetracycline
Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs
Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs
[PMID: 17088489]
In Vitro

Tetracycline shows susceptibilfty of V. vulnlflcus strain B3547 with MIC value of 0.5 g/mL[2].
Tetracycline inhibits the L-amyloid aggregates formation and disassembles the pre-formed fibrils[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pretreatment with Ketoconazole (KTC) (HY-B0105) prevented the animals from 8-Epidiosbulbin E acetate-induced liver injury, caused 7- and 13-fold increases in plasma Cmax and AUC of 8-Epidiosbulbin E acetate, and decreased urinary excretion of glutathione (GSH) conjugates derived from 8-Epidiosbulbin E acetate[1].
8-Epidiosbulbin E acetate can be used in animal modeling to construct models of liver deseases[1][2].

Induction of tumor regression based on BCR-ABL gene silencing[4]

Background
The BCR-ABL gene encodes an abnormal tyrosine kinase (BCR-ABL protein), which leads to uncontrolled cell proliferation. Tetracycline can induce tumor regression in mice by inhibiting BCR-ABL expression through the suppression of the binding between tTA (tetracycline transactivator) and the Tet-OP (Tetracycline Operator) sequence[4].
Specific Mmodeling Methods
Mice: nu/nu • female and male • 6-8 weeks old
Administration: 200 μg/ml • po • single dose
Note
1.Tetracycline is administered orally dissolved in drinking water containing 5% sucrose.
2.Mouse tumor model construction: To induce visible tumors, Ba/F3 cells transduced with SIN-p210 (a retrovirus carrying and inducing tetracycline-dependent BCR-ABL gene expression) are subcutaneously injected into nude mice.
Modeling Indicators
Phenotypic observation: The tumors established in the mice completely regress.
Correlated Product(s): /
Opposite Product(s): /

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female ICR mice weight 30 to 40 g with V.vulnificus strain B3547 infection[2]
Dosage: 3 mg/kg
Administration: Intraperitoneal injection; 3 mg/kg every 12h until survive
Result: Inhibited the growth of human CNE-2 xenografts in nude mice.
Clinical Trial
Molecular Weight

444.43

Formula

C22H24N2O8

CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(C(C1=O)=C(O)[C@@H](N(C)C)[C@]2([H])C[C@]3([H])[C@](C)(O)C4=C(C(C3=C(O)[C@@]21O)=O)C(O)=CC=C4)N

Structure Classification
Initial Source

Shigella dysenteriae

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years

*The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility
In Vitro: 

DMSO : 125 mg/mL (281.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.2501 mL 11.2504 mL 22.5007 mL
5 mM 0.4500 mL 2.2501 mL 4.5001 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*The compound is unstable in solutions, freshly prepared is recommended.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: ≥98.0%

References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.2501 mL 11.2504 mL 22.5007 mL 56.2518 mL
5 mM 0.4500 mL 2.2501 mL 4.5001 mL 11.2504 mL
10 mM 0.2250 mL 1.1250 mL 2.2501 mL 5.6252 mL
15 mM 0.1500 mL 0.7500 mL 1.5000 mL 3.7501 mL
20 mM 0.1125 mL 0.5625 mL 1.1250 mL 2.8126 mL
25 mM 0.0900 mL 0.4500 mL 0.9000 mL 2.2501 mL
30 mM 0.0750 mL 0.3750 mL 0.7500 mL 1.8751 mL
40 mM 0.0563 mL 0.2813 mL 0.5625 mL 1.4063 mL
50 mM 0.0450 mL 0.2250 mL 0.4500 mL 1.1250 mL
60 mM 0.0375 mL 0.1875 mL 0.3750 mL 0.9375 mL
80 mM 0.0281 mL 0.1406 mL 0.2813 mL 0.7031 mL
100 mM 0.0225 mL 0.1125 mL 0.2250 mL 0.5625 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Tetracycline
Cat. No.:
HY-A0107
Quantity:
MCE Japan Authorized Agent: